Key result
Catheter-based ventricle-to-coronary vein bypass (VPASS) was feasible in a swine model, achieving retrograde flow with a maximal velocity of 37 +/- 7 cm/sec and maintaining 30-day implant patency.
Why the study?
Does a catheter-based ventricle-to-coronary vein bypass (VPASS) achieve retrograde myocardial perfusion in a swine model?
Does a catheter-based ventricle-to-coronary vein bypass (VPASS) achieve retrograde myocardial perfusion in a swine model?
Catheter-based ventricle-to-coronary vein bypass is feasible in a swine model and may offer a novel approach for treating end-stage myocardial ischemia.
Supports preclinical VPASS development; leaves open translation to human refractory ischemia.
The goal of this study was to investigate the feasibility of a catheter-based ventricle-to-coronary vein bypass (VPASS) in order to achieve retrograde myocardial perfusion by a conduit (VSTENT) from the left ventricle (LV) to the anterior interventricular vein (AIV). Percutaneous coronary venous arterialization has been proposed as a potential treatment strategy for otherwise untreatable coronary artery disease. In an acute setting, the VSTENT implant was deployed percutaneously using the VPASS procedure in five swine. Coronary venous flow and pressure patterns were measured before and after VSTENT implant deployment with and without AIV and left anterior descending artery (LAD) occlusion. In a separate chronic pilot study, the VPASS procedure was completed on two animals that had a mid-LAD occlusion or LAD stenosis. At day 30 post-VPASS procedure, left ventriculography and magnetic resonance imaging (MRI) were performed to assess the patency and myocardial viability of the VSTENT implants. Pre-VSTENT implantation, the mid-AIV systolic wedge pressure was significantly lower than LV systolic pressure during AIV blockage (46 +/- 19 vs. 90 +/- 16 mm Hg; P < 0.01). The VSTENT implant deployment was performed without complication and achieved equalization of the AIV and LV systolic pressures and creation of retrograde flow in the distal AIV (maximal flow velocity: 37 +/- 7 cm/sec). At day 30 post-VPASS procedure, left ventriculography showed VSTENT implant patency. MRI perfusion images demonstrated myocardial viability even with an LAD occlusion. Coronary retrograde perfusion using the VPASS procedure is feasible and may represent a potential technique for end-stage myocardial ischemia.
No takes yet. Share an insight, caveat, or question.
Hayase et al. (2005) studied Coronary artery disease / end-stage myocardial ischemia (n=7). Catheter-based ventricle-to-coronary vein bypass (VPASS) with VSTENT was evaluated on Feasibility, coronary venous flow and pressure patterns, and implant patency. Catheter-based ventricle-to-coronary vein bypass (VPASS) was feasible in a swine model, achieving retrograde flow with a maximal velocity of 37 +/- 7 cm/sec and maintaining 30-day implant patency.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: